Loading

JSM Ophthalmology

Comparative In vitro Cytotoxicity of Artificial Tears

Research Article | Open Access | Volume 3 | Issue 1

  • 1. Byers Eye Institute at Stanford, USA
+ Show More - Show Less
Corresponding Authors
Christopher N. Ta, Byers Eye Institute at Stanford, 2452 Watson Court MC 5353, Palo Alto, CA 94303, Tel: 650- 723-6995, Fax: 650- 565-8297
RESULTS AND DISCUSSION

The results of the MTT assay yielded consistent results. We here describe the assay results as a percentage of the metabolic activity in control media (positive control). As expected the preservative BAK (18.5%, p=.006) and formalin (21.1%, p=0.007) yielded the lowest assay results as compared to positive control media solution. Among the tested artificial tears, Systane® with preservative (30.5%, p=0.006) and Blink® with preservative (34.4%, p=0.007) yielded the lowest assay results. Genteal® (39.3%, p=0.006) was next, followed by Systane® PreservativeFree (66.0%, p=0.01), Thera-tears® (67.4%, p=0.009), and Blink® Preservative-Free (74.2%, p=0.009). Refresh® (92.6%, p=0.012) and Refresh® Preservative-Free (104.4% p=0.01) performed the best on the assay and showed little to no toxicity (Figure 1).

Using ANOVA testing we can divide the artificial tears into groups. Blink® (34.4%), Systane® with preservative (30.5%), and Genteal® (39.3%) were significantly more cytotoxic than the other brands but were not significantly different from each other. Blink® Preservative-Free (74.2%), Thera-Tears® (67.4%) and Systane® Preservative-Free (66.0%) were the next group. They were less cytotoxic than the first group, but not significantly different from each other. Refresh® (92.6%) and Refresh® Preservative-Free (104.4%) demonstrated the least cytotoxicity but were not significantly different from each other.

Preservative-free formulations of artificial tears were significantly less toxic than their preservative-containing counterparts for all brands. This was seen most in Systane® and Blink® with Systane® Preservative-Free yielding a MTT assay result 2.16 times higher than Systane® with preservative (p<0.001) and Blink® Preservative-Free yielding an assay result 2.16 times higher than Blink® with preservative (p<0.001). The difference was less dramatic but still present for Refresh® Preservative-Free, with its assay result being only 1.13 times higher in that of Refresh® with preservative (p<0.001) (Figure 1).

In a comparison of the different dilutions and thus concentration-dependent toxicity, there appears to be change in toxicity with diluted test samples. For the products containing polyethylene glycol as their active ingredient, being Blink®, Systane® and their preservative-free counterparts, there appeared to be less toxicity as the product became more dilute. This was especially true for the preservative-containing formulations, with 12.5% dilution of Blink® having 3.00 times more metabolic activity than undiluted Blink® (p=0.004) and 12.5% dilution of Systane® having 2.90 times more metabolic activity than undiluted Systane® (p=0.009). The effect was not as dramatic in the preservative-free formulations: the 12.5% dilutions of those had 1.22 and 1.26 times more metabolic activity than the original concentration in preservative-free Blink® and Systane®, respectively. Also for Genteal®, in which the active ingredient is hypromellose, there was a mild dilution-dependent increase in metabolic activity (Figure 2).

In contrast, dilution in the carboxymethylcellulose- containing products (Refresh®, Refresh® Preservative-Free) was associated with somewhat lower metabolic activity. The 12.5% dilutions of each of these had 0.93, 0.83, and 0.86 times as much metabolic activity as their undiluted counterparts, respectively. It is interesting that the metabolic activity decreases with dilution of these compounds and we speculate there could be an ingredient in their formulations, possibly carboxymethylcellulose, which promotes there in vitro metabolic activity and that this effect decreases with dilution (Figure 2).

Our results show that Refresh® and Refresh® PreservativeFree had the least in vitro cytotoxicity among the different solutions tested. The active ingredient of both brands is sodium carboxymethylcellulose (CMC). This suggests that CMC is perhaps the least toxic active ingredient. The relatively good performance of the only other product containing CMC, Thera-Tears®, is also supportive of this, as it outperformed all non-CMC products; except for Blink® Preservative-Free. The products with the most cytotoxicity were Blink® and Systane® in their preservativecontaining formulations. The active ingredient in these products is polyethylene glycol (PEG). However, because of the relatively good performance of the preservative-free formulations of these two brands, PEG is not likely the cause of the relative cytotoxicity of Blink® and Systane®. Rather, the cause is likely the preservatives in these two products.

Blink® uses the preservative OcuPure® (Sodium chlorite; stabilized oxychloro complex 0.005% m/v) and Systane® contains the preservative PolyQuad® (polyquaternium-1) 0.001%. If we examine the dilution-dependent performance of these two products, we note that there is dramatic increase in metabolic activity as we dilute the products to 50% and then 25%. This suggests that as the concentration of preservative decreases, the toxicity of these two products decreases dramatically as well. This agrees with the results from the preservative-free formulations of Blink® and Systane®, for which we find that there is little change in cytotoxicity as the products are diluted.

Interestingly, there is minimal decrease in cytotoxicity as the preservative in Refresh® is diluted. Refresh® uses Purite™ (stabilized oxychloro complex 0.005% m/v). Given the relatively low cytotoxicity of Refresh®, even at its full concentration, and the lack of change with dilution, it appears that Purite™ is, in vitro at least, possibly a less toxic preservative than those found in Systane® and Blink®. In addition, though to a greater degree with Systane® and Blink® than Refresh®, our results align with previous reports of preservative-free ocular solutions being generally less cytotoxic than preservative-containing ones. [6,8-11] Though clearly the preservative containing formulations performed worse in our study, the advantages of having preservative in regard to cost and shelf life justify their availability.

Examining the formulations without preservatives, we still observe that the CMC-containing products tend to be less cytotoxic than the PEG-containing products. The reasons for this are open to speculation. We do know that the mechanisms by which PEG and CMC lubricate the ocular surface are likely to be quite different. PEG is a charge-neutral polymer that is hydrophilic by virtue of the oxide moieties along its chain. By contrast, CMC is a derivative of cellulose that contains carboxymethyl groups (-CH2 - COOH) bound to some of the hydroxyl groups on its backbone. It is most often used as a sodium salt, in which case the polymer is negatively charged. This renders the material highly hydrophilic. By virtue of its charge, it mostly likely interacts in a different way from PEG with both the tear film and the ocular surface.

Prior work in corneal epithelial cytotoxicity has been generally focused on glaucoma medications.[6-8,10,11] Other studies have focused on the preservatives used in solutions. Polyquaternium, the preservative in Systane®, was found to not inhibit the cytokinetic movement or mitotic activity epithelial cells [9]. However another study showed polyquaternium increased inflammatory marker secretion in vitro [12]. Perborate, the preservative in Genteal®, was found to have similar toxicity to EDTA 0.01% [5]. Our study is the first to examine in vitro cytoxicity in a range of popularly used artificial tear medications.

We must be careful, however, to not equate the in vitro conditions of our study with the in vivo conditions of the human eye. Indeed some recent in vivo studies have not found products containing CMC to be superior to PEG [13,14]. The most that can be concluded from our study is that one particular formulation— that is, its ingredients in concert—is more or less cytotoxic than another in this particular in vitro setting. The application of these drops directly over a monolayer of cells is not entirely reflective of what happens in vivo. Finally, all of these formulations contain variations of buffering solutions that may influence the performance of the products in these assays, making it difficult to elucidate the exact cytotoxic profiles of the active ingredients themselves.

Table 1: Composition of Artificial Tear Products Tested. Active ingredient and preservatives of the tested products.

Brand Preservative Active Ingredient
Blink® Tears Lubricating Eye Drops1 OcuPure®(Sodium chlorite; stabilized oxychloro complex 0.005% m/v) Polyethylene glycol 400 0.25%
Blink® Tears Preservative Free Lubricating Eye Drops[1] none Polyethylene glycol 400 0.25%
Refresh Tears® Moisture drops for dry eyes[2] Purite™ (Stabilized oxychloro complex 0.005% m/v) Sodium carboxymethylcellulose 0.5%
Refresh Plus® Moisture drops for dry eyes, Sensitive, preservative-free[2] none Sodium carboxymethylcellulose 0.5%
Systane® Ultra Lubricant Eye Drops[3] PolyQuad® (polyquaternium-1) 0.001% Polyethylene glycol 400 0.4%, Propylene glycol 0.3%
Systane® Ultra Lubricant Eye Drops PreservativeFree Formula[3] none Polyethylene glycol 400 0.4%, Propylene glycol 0.3%
Genteal® Lubricant Eye Drops3 GenAqua™ (Sodium perborate) Hypromellose 0.3%
TheraTears® Lubricant Eye Drops[4] Sodium perborate Sodium carboxymethylcellulose 0.25%
[1]Abbott Laboratories Inc., Abbott Park, IL. [2]Allergan, Inc., Irvine, CA. [3]Alcon Laboratories, Inc., Fort Worth, TX. [4]Akorn, Inc., Lake Forest, IL.

 

 

 

 

 

 

 

 

 

 

 

CONCLUSION

We must be careful, however, to not equate the in vitro conditions of our study with the in vivo conditions of the human eye. Indeed some recent in vivo studies have not found products containing CMC to be superior to PEG [13,14]. The most that can be concluded from our study is that one particular formulation— that is, its ingredients in concert—is more or less cytotoxic than another in this particular in vitro setting. The application of these drops directly over a monolayer of cells is not entirely reflective of what happens in vivo. Finally, all of these formulations contain variations of buffering solutions that may influence the performance of the products in these assays, making it difficult to elucidate the exact cytotoxic profiles of the active ingredients themselves.

REFERENCES

1. Bron AJ, Tomlinson A, Foulks GN, Pepose JS, Baudouin C, Geerling G, et al. Rethinking dry eye disease: a perspective on clinical implications. Ocul Surf. 2014; 12: S1-31.

2. Dogru M, Tsubota K. Pharmacotherapy of dry eye. Expert Opin Pharmacother. 2011; 12: 325-334.

3. Ammar DA, Kahook MY. Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells. Mol Vis. 2011; 17: 1806-1813.

4. Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010; 29: 312-334.

5. Epstein SP, Ahdoot M, Marcus E, Asbell PA. Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells. J Ocul Pharmacol Ther. 2009; 25: 113-119.

6. Nakagawa S, Usui T, Yokoo S, Omichi S, Kimakura M, Mori Y, et al. Toxicity evaluation of anti-glaucoma drugs using stratified human cultivated corneal epithelial sheets. Invest Ophthalmol Vis Sci. 2012; 53: 5154-5160

7. Pauly A, Roubeix C, Liang H, Brignole-Baudouin F, Baudouin C. In vitro and in vivo comparative toxicological study of a new preservative-free latanoprost formulation. Invest Ophthalmol Vis Sci. 2012; 53: 8172- 8180.

8. Whitson JT, Petroll WM. Corneal epithelial cell viability following exposure to ophthalmic solutions containing preservatives and/or antihypertensive agents. Adv Ther. 2012; 29: 874-888.

9. Tripathi BJ, Tripathi RC, Kolli SP. Cytotoxicity of ophthalmic preservatives on human corneal epithelium. Lens Eye Toxic Res. 1992; 9: 361-375.

10. Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008; 86: 716-726.

11. Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloridepreserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther. 2010; 27: 837-845. 

12. Paimela T, Ryhänen T, Kauppinen A, Marttila L, Salminen A, Kaarniranta K. The preservative polyquaternium-1 increases cytoxicity and NFkappaB linked inflammation in human corneal epithelial cells. Mol Vis. 2012; 18: 1189-1196.

13. Cohen S, Martin A, Sall K. Evaluation of clinical outcomes in patients with dry eye disease using lubricant eye drops containing polyethylene glycol or carboxymethylcellulose. Clin Ophthalmol. 2014; 8: 157-164.

14. Tung CI, Kottaiyan R, Koh S, Wang Q, Yoon G, Zavislan JM, et al. Noninvasive, objective, multimodal tear dynamics evaluation of 5 over-the-counter tear drops in a randomized controlled trial. Cornea. 2012; 31: 108-114

Citation

Zheng LL, Myung D, Yu CQ, Ta CN (2015) Comparative In vitro Cytotoxicity of Artificial Tears. JSM Ophthalmol 3(1): 1026.

Abstract

Artificial tears are some of the most commonly used ocular medications. The relative cytotoxicity of the most popular brands is not well established. In this study corneal epithelial cells were cultured in the presence of popular brands of artificial tears of varying concentrations. The cellular metabolic activity was then assessed with MTT ((3- (4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) colorimetric cytotoxicity assay and the results compared. We found preservative-free artificial tears were significantly less cytotoxic than their preservative containing counterparts. Products based on carboxymethylcellulose tended to be less cytotoxic than those based on polyethylene glycol. Among non-preserved artificial tears Refresh® Preservative-Free was found to be least cytotoxic to cultured epithelial cells. Among artificial tears with preservatives Systane®, Blink®, and Genteal® were found to have the most in vitro cytotoxicity. This study demonstrates significant differences in the in vitro toxicity of popular artificial tears.

Keywords

Cytotoxicity , Artificial tears , Corneal epithelium

INTRODUCTION

Dry eye is one of the most common ocular conditions in the world with prevalence of over 10 million in the United States alone [1]. It can result in severe ocular symptoms and visual disability. The primary treatment for dry eyes is instillation of artificial tears over the course of the day [2]. The role of artificial tears is to either replace or augment the native tear film, with the goal of maintaining ocular surface lubrication.

While the drop-wise concentration of the ingredients in artificial tears is relatively low, the cumulative dose can be high when taken over many years, as is often the case. This is especially important in the context of the ancillary ingredients, such as preservatives and stabilizing agents, some of which are known to be cytotoxic [3-8]. In fact, it is their cytotoxicity that is leveraged to inhibit microbial overgrowth and thus improve shelf life and promotes sterility. Thus, there is a risk of toxicity that must be balanced against the benefit of ocular surface lubrication. Recently, there has been a surge of “preservativefree” formulations that have been manufactured without the addition of potentially cytotoxic agents, though at the expense of shelf life and relative sterility.

In this study, a number of commercially available artificial tear preparations were compared in an in vitro cytotoxicity study on cultured human corneal epithelial cells. The products included: Blink®, Blink® Preservative-Free, Refresh®, Refresh® Preservative-Free, Systane®, Systane® Preservative-Free, Thera-Tears®, and Genteal®. Each product was tested alongside the commonly added preservative benzalkonium chloride (BAK; Alfa Aesar, Ward Hill, MA). Lastly, the cytotoxicity of these artificial tears was also studied as a function of concentration by dilution of the full strength product.

MATERIALS AND METHODS

Cell Line

Human corneal epithelial cells immortalized with Adenovirus 12-SV40 hybrid virus (HCE-2 [50.B1]) were obtained from American Type Culture Collection (ATCC, Manassas, VA). Cells were cultured on polystyrene plates coated with 0.01 mg/mL bovine fibronectin (Sigma-Aldrich, St. Louis, MO) and 0.03 mg/ mL collagen type I (PureCol, Advanced Bio Matrix, San Diego, CA), and maintained at 37?C with 5% CO2 in keratinocyte serum-free medium (Invitrogen, Carlsbad, CA) supplemented with 0.05 mg/ mL bovine pituitary extract, 5 ng/mL epidermal growth factor, 0.005 mg/mL human insulin, 500 ng/mL hydrocortisone, and 1% antibiotics/antimycotics (Invitrogen, Carlsbad, CA). Cells from passages 5 to 10 were used for experiments.

Preparation of Artificial Tears and Reagents

Three brands of lubricant eye drops, both in preserved and preservative-free forms, were obtained over-the-counter: (1) Blink® Tears Lubricating Eye Drops and (2) Blink® Tears Preservative-Free Lubricating Eye Drops (Abbott Laboratories Inc., Abbott Park, IL); (3) Systane® Ultra Lubricant Eye Drops and (4) Systane® Ultra Lubricant Eye Drops PreservativeFree Formula (Alcon Laboratories, Inc., Fort Worth, TX), (5)  Refresh® Plus® Moisture drops for dry eyes and (6) Refresh® Tears® Moisture drops for dry eyes, sensitive, preservativefree (Allergan, Inc., Irvine, CA). Two other lubricant drops with preservatives were also tested: (7) Genteal® Lubricant Eye Drops (Alcon), and (8) TheraTears® Lubricant Eye Drops (Akorn, Inc., Lake Forest, IL) (Table 1).

Dilutions

Dilutions of artificial tears ranging from a concentration of 100% to 12.5% were prepared with phosphate buffered saline pH 7.4 (PBS, Invitrogen, Carlsbad, CA).

MTT Assay

MTT ((3-(4,5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) cell proliferation assay (ATCC, Manassas, VA) was used to quantify viable cells after exposure to artificial tear solutions. The tetrazolium salt MTT is reduced by metabolically active cells to generate intracellular purple formazan that can be solubilized and quantified. Previously, length of the MTT incubation period had been optimized to 2 hours for this cell line to produce spectrophotometric readings that fell within a linear range for the relevant cell counts.

Five thousand corneal epithelial cells were seeded into precoated 96-well tissue culture polystyrene plates (Cellstar; Greiner Bio-One, Monroe, NC) and cultured for 3 days to reach confluence. Prior to incubation in artificial tear and control solutions, wells were washed with PBS pH 7.4. Corneal epithelial cells were incubated in 100 µL of artificial tear or control solutions for 1 hour at 37?C and 5% CO2 . All wells were washed three times with PBS to remove remnant artificial tear solution.

Wells were incubated in 100 µL of complete culture medium containing 10% MTT and incubated for 2 hours at 37?C and 5% CO2 . The same volume of detergent reagent (MTT Cell Proliferation Assay; ATCC, Manassas, VA) was used to dissolve the intracellular formazan at room temperature in the dark for 2 hours. Absorbance readings were measured at 570 nm with a microtiter plate reader (BioTek Instruments, Inc., Winooski, VT). 

Controls

All solutions were tested five times in parallel with positive and negative controls. Negative controls consisted of formalin at 10% and 0.01% w/v BAK, and these were used to establish the cytotoxic baseline MTT absorbance. Positive control was cell culture media, and this was used to established the signal strength of what is to be considered non-toxic “fully” biocompatible. For the dilutions 0.01% BAK was also similarly diluted and used as negative control for the assay. All solutions except 10% formalin were warmed in a 37?C, 5% CO2 incubator.

Statistical Analysis

Statistical analyses were performed with commercially available software (SPSS for PC, Version 20.0, SPSS, Chicago, Illinois). Comparisons of the means between two sets of data were formed using unpaired test students T tests. Comparisons of means for more than two sets of data were performed using one way ANOVA. All p-values were 2-sided and considered significant if <0.05.

 

Received : 16 Nov 2014
Accepted : 29 Jan 2015
Published : 31 Jan 2015
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X